First FDA Approved Medicine Manufactured Using 3D Printing Technology Now Available

SPRITAM® is Designed to Transform Experience of Taking Epilepsy Medication BLUE ASH, Ohio, March 22, 2016 – Aprecia Pharmaceuticals today announced that SPRITAM® (levetiracetam) tablets, for oral suspension, is now available as an adjunctive therapy in the treatment of partial onset seizures, myoclonic seizures and Read More »

Image courtesy of Aprecia

FDA Approves the First 3D Printed Drug Product

Aprecia Introduces its First Product Using the ZipDose® Formulation Platform for the Treatment of Epilepsy   BLUE ASH, Ohio, August 3, 2015 – Aprecia Pharmaceuticals Company today announced that the U.S. Food and Drug Administration (FDA) has approved SPRITAM® levetiracetam for oral use as a Read More »

Image courtesy of Aprecia Pharmaceuticals Company